HPV9 vaccine / GSK - LARVOL DELTA

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age (clinicaltrials.gov) - P1/2 | N=1080 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | Phase classification: P2 ➔ P1/2

Phase classification • Trial completion • Gynecology • Oncology

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age (clinicaltrials.gov) - P2 | N=1080 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P2

Enrollment closed • Phase classification • Gynecology • Oncology

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age (clinicaltrials.gov) - P1/2 | N=1080 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting | Phase classification: P2 ➔ P1/2

Enrollment open • Phase classification • Gynecology • Oncology